UC patient portrait

NOW APPROVED FOR UC

LASTING* REMISSION CAN START WITH STELARA®

For Your Adult Patients With Moderately to Severely Active UC

*In both the UC and CD studies, many patients achieved clinical remission at 1 Year with STELARA®.

RAPID RESPONSE

Clinical response was achieved as early as Week 8 in UC (secondary endpoint) clinical trials1

LASTING REMISSION

Clinical remission was achieved as early as Week 8 and at 1 year in UC clinical trials1

HISTO-ENDOSCOPIC MUCOSAL IMPROVEMENT (HEMI)

The first and only FDA-approved UC treatment to achieve HEMI. Some patients with UC achieved HEMI with STELARA® at the designated time points (Week 8 and 1 Year) in clinical trials1,2§

DEMONSTRATED SAFETY PROFILE

The overall safety profile of STELARA® in UC was consistent with that seen in other approved indications1

 

 

JANSSEN CAREPATH SAVINGS PROGRAM

Eligible patients pay $5 per dose

$20,000 maximum program benefit per calendar year

See full program requirements

Janssen CarePath Savings Program: Eligible patients using commercial insurance to pay for their medication can save on their out-of-pocket medication costs for STELARA®. Eligible patients pay $5 per dose, with a $20,000 maximum program benefit per calendar year. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement. Program does not cover the cost to give patients their treatment. See full eligibility requirements

CD=Crohn’s disease; UC=ulcerative colitis.

†Clinical response was defined as a decrease from baseline in the modified Mayo score by ≥30% and ≥2 points, with either a decrease from baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1.

‡Clinical remission was defined as Mayo stool frequency subscore of 0 or 1, Mayo rectal bleeding subscore of 0, and Mayo endoscopy subscore of 0 or 1 (modified so that 1 does not include friability).

§HEMI was defined as combined endoscopic improvement (Mayo endoscopy subscore of 0 or 1) and histologic improvement of the colon tissue (neutrophil infiltration in <5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue).

References: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech,Inc. 2. Data on file. Janssen Biotech, Inc.